Industry

Reproxalap Statistically Superior to Vehicle for Both Primary Endpoints of Ocular Redness (P=0.0004) and Schirmer Test (P=0.0005) Schirmer Test ≥10mm Responder Analysis Multiplicity-Controlled Secondary Endpoint Achieved (P=0.0361) Secondary Endpoints Achieved for All Symptoms Assessed: Dryness (P=0.0068), Discomfort (P<0.0001), Grittiness (P=0.0001), Stinging (P=0.0001), Burning (P<0.0001), and Itching (P=0.0003) Company to Host Conference Call at 8:00 a.m. … [Read more…]

Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised its … [Read more…]

BOSTON–(BUSINESS WIRE)–Etiometry, a leader in clinical decision-support software for critical care, announced today that it has doubled its FDA-cleared risk analytics portfolio to four indices, further strengthening its capability to track the fundamental pathways through which patients deteriorate under intensive care. Etiometry is the only critical care AI decision-support company with four FDA-cleared algorithms. The … [Read more…]

Mental health a key indicator; 58% of adults negatively affected by pandemic INDIANAPOLIS–(BUSINESS WIRE)–Arlington, Virginia, has been named “America’s Fittest City” in the annual American Fitness Index® rankings published by the American College of Sports Medicine (ACSM) and the Elevance Health Foundation, the philanthropic arm of Elevance Health. The ACSM / Elevance Health Foundation Fitness … [Read more…]

Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 Cash and cash equivalents at May 31, 2022 were $28.8 million Full-Year 2022 … [Read more…]

STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. As previously announced, the Phase III clinical trial was placed on clinical hold by … [Read more…]

EVERETT, Wash.–(BUSINESS WIRE)–Fluke Biomedical announced the OneQA test and workflow automation software now supports the top-selling ProSim 8 multifunction patient simulator. Fluke Biomedical OneQA is an industry-leading quality assurance software platform that helps hospitals, independent service organizations and OEM service teams increase the safety, efficiency, and accuracy of medical equipment testing and quality assurance workflows. … [Read more…]

– $55 million Series A financing will advance the company’s robust preclinical pipeline and ongoing discovery efforts – – Epic holds exclusive license to smallest known Cas protein, enabling in vivo delivery via AAV vector to wide range of target organs – – Lead program in facioscapulohumeral muscular dystrophy (FSHD) on track for clinical initiation … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “NGS Oncology Market – A Global and Regional Analysis: Focus on Offering, Sequencing Technology, Workflow, Application, End User, and Region – Analysis and Forecast, 2022-2032” report has been added to ResearchAndMarkets.com’s offering. Global NGS Oncology Market Industry Overview The global NGS oncology market is projected to reach $51,783.0 million in 2032 from 14,828.6 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Hematologic Malignancies Testing Market: Focus on Hematologic Malignancies Testing Product and Application, Supply Chain Analysis, and Country Analysis – Analysis and Forecast, 2022-2032” report has been added to ResearchAndMarkets.com’s offering. Hematologic Malignancies Testing Market: Industry Overview The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from … [Read more…]